395
Participants
Start Date
December 31, 2010
Primary Completion Date
May 31, 2012
Study Completion Date
May 31, 2012
oxycodone HCl and naltrexone HCl extended-release capsules
Daily dose range of 20 mg to 160 mg of the oxycodone component in a 24 hour time interval, administered twice daily approximately 12 hours apart (At the discretion of the Investigator, oxycodone HCl and naltrexone HCl extended-release capsules may be administered once daily, at 24 hour intervals.)
Drug Trials America - New York, Hartsdale
New York Spine and Wellness Center, North Syracuse
Upstate Clinical Research Associates, Williamsville
Allegheny Pain Management, PC, Altoona
Crossroads Research, Owings Mills
Hypothetest, LLC, Roanoke
Center for Clinical Research, LLC - Winston-Salem, Winston-Salem
Drug Studies America, Marietta
Georgia Institute for Clinical Research, LLC, Marietta
Center for Prospective Outcome Studies, Inc., Atlanta
Accord Clinical Research, Port Orange
Ormond Medical Arts Pharmaceutical Research Center, Ormond Beach
Peninsula Research, Inc., Ormond Beach
Florida Institute of Medical Research, Jacksonville
Avail Clinical Research, LLC, DeLand
Drug Study Institute, Jupiter
Clinical Research of West Florida, Tampa
Sarasota Pain Medicine Research, Sarasota
Mid-South Anesthesia Consultants, Southaven
The Pain Treatment Center of the Bluegrass, Lexington
Commonwealth Biomedical Research, Madisonville
Columbus Clinical Research, Inc., Columbus
MAPS Applied Research Center, Edina
Montana Neuroscience Institute, Missoula
Healthcare Research, LLC, Hazelwood
KRK Medical Research, Dallas
Benchmark Research - Fort Worth, Fort Worth
Quality Research, Inc., San Antonio
FutureSearch Trials of Neurology, Austin
Lifetree Clinical Research, Salt Lake City
DM Clinical Research, Springfield
Comprehensive Clinical Research, Berlin
Lead Sponsor
Pfizer
INDUSTRY